Wet Age-related Macular Degeneration - Pipeline Insights, 2017

  • ID: 4436378
  • Drug Pipelines
  • Region: Global
  • 106 Pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Acucela
  • Allergan
  • Daiichi Sankyo
  • Novartis
  • others
  • Quark
  • MORE

Wet Age-related Macular Degeneration - Pipeline Insights, 2017 provides comprehensive insights about pipeline drugs across this indication. This report further provides information on the therapeutic development of more than 20+ pipeline drugs at various stages covering Phase III, Phase II and Phase I and contains a comparative assessment by product type, route of administration and molecule type. More than half of the clinical products are undergoing Phase II clinical studies and three had entered late stage (Phase III) of development. The report also provides list of 25+ (Pre-clinical and Discovery) products. Further, The report contains list of the 25+ dormant products in this space. Leading companies in this space are Novartis, OHR Pharmaceutical, Allergan and Opthotech.

Comparative analysis of pipeline drugs at various stages and their therapeutic assessment by product type and molecule type provides additional and vital details of the pipeline drugs. Information on various technologies involved in the development of pipeline therapeutics along with all the collaborations and agreements of the respective company brings added the advantage of this report. Patent and Financing details related to the products are also provided.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acucela
  • Allergan
  • Daiichi Sankyo
  • Novartis
  • others
  • Quark
  • MORE
  1. Overview
  2. Age-Related Macular Degeneration
  3. Risk factors for AMD
  4. Wet AMD - Pathogenesis
  5. Wet AMD - Clinical Features & Diagnosis
  6. Wet AMD - Treatment Options
  7. Pipeline Therapeutics (Active Products)
  8. Comparative Analysis
  9. Late Stage Products (Phase III)
  10. Comparative Analysis
  11. Abicipar: Allergan
  12. Product Description
  13. Research and Development
  14. Product Development Activities
  15. More drugs in detailed report
  16. Mid Stage Products (Phase II)
  17. Comparative Analysis
  18. DE-122: Santen Pharmaceutical
  19. Product Description
  20. Research and Development
  21. Product Development Activities
  22. More drugs in detailed report
  23. Early Stage Products (Phase I)
  24. Comparative Analysis
  25. AS101: BioMAS
  26. Product Description
  27. Research and Development
  28. More drugs in detailed report
  29. Pre-clinical & Discovery Stage Products
  30. Therapeutic Assessment: Active Products
  31. Assessment by Monotherapy Products
  32. Assessment by Combination Products
  33. Assessment by Route of Administration
  34. Assessment by Stage and Route of Administration
  35. Assessment by Molecule Type
  36. Assessment by Stage and Molecule Type
  37. Inactive Products
  38. Appendix

List of Tables
Table 1: Total Products for Wet Age-related Macular Degeneration
Table 2: Late Stage Products (Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical & Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: List of Inactive Products

List of Figures
Figure 1: Fundus photographs of healthy and AMD affected eyes
Figure 2: Progression of AMD
Figure 3: Mechanism of Neovascularisation
Figure 4: Total Products for Wet Age-related Macular Degeneration
Figure 5: Late Stage Products (Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I and IND)
Figure 8: Pre-clinical & Discovery Stage Products
Figure 9: Assessment by Monotherapy Products
Figure 10: Assessment by Combination Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Molecule Type
Figure 14: Assessment by Stage and Molecule Type
Figure 15: Inactive Products

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acucela
  • Adalta
  • Adverum Biotechnologies
  • Aerie Pharmaceuticals
  • Allergan
  • Benitech Biopharma
  • Charlesson
  • Coherus Biosciences
  • Daiichi Sankyo
  • GreyBug Vision
  • Hemera Biosciences
  • MeiraGTx
  • Novartis
  • Ocular Therapeutix
  • OHR Pharmaceutical
  • Opthotech Corporation
  • Oxford Biomedica
  • PanOptica
  • pSivida
  • Quark
  • Regeneron
  • Roche
  • RXI Pharmaceuticals
  • SciFluor Life Sciences
  • others
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll